AICA ribonucleotide (AICAR) is an intermediate in the generation of inosine monophosphate and an analog of adenosine monophosphate (AMP).
It is capable of stimulating AMP-dependent protein kinase (AMPK) activity, making it a potential therapeutic agent for metabolic diseases such as type 2 diabetes.
AICAR has also been investigated for its role in increasing metabolic activity and altering muscle composition. Additionally, it has been implicated in performance-enhancing applications, leading to its inclusion on the World Anti-Doping Agency’s prohibited substances list.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | AICA ribonucleotide, AICAR monophosphate, Z-nucleotide, 5-amino-4-imidazolecarboxamide ribotide |
|---|---|
| IUPAC Name | [(2R, 3S, 4R, 5R)-5-(5-amino-4-carbamoylimidazol-1-yl)-3, 4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate |
| CAS | 3031-94-5 |
| Molecular Weight | 338.21 |
| Molecular Formula | C9H15N4O8P |
| SMILES | C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)N)C(=O)N |
